195 related articles for article (PubMed ID: 26799632)
1. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.
Freude S; Heise T; Woerle HJ; Jungnik A; Rauch T; Hamilton B; Schölch C; Huang F; Graefe-Mody U
Diabetes Obes Metab; 2016 May; 18(5):483-90. PubMed ID: 26799632
[TBL] [Abstract][Full Text] [Related]
2. Selective Inhibition of 11beta-Hydroxysteroiddehydrogenase-1 with BI 187004 in Patients with Type 2 Diabetes and Overweight or Obesity: Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Dosing Over 14 Days.
Bianzano S; Schepers C; Wolff M; Heise T; Plum-Moerschel L
Exp Clin Endocrinol Diabetes; 2022 Dec; 130(12):773-782. PubMed ID: 36343645
[TBL] [Abstract][Full Text] [Related]
3. Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).
Webster SP; McBride A; Binnie M; Sooy K; Seckl JR; Andrew R; Pallin TD; Hunt HJ; Perrior TR; Ruffles VS; Ketelbey JW; Boyd A; Walker BR
Br J Pharmacol; 2017 Mar; 174(5):396-408. PubMed ID: 28012176
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity.
Bianzano S; Heise T; Jungnik A; Schepers C; Schölch C; Gräfe-Mody U
Clin Diabetes Endocrinol; 2021 Aug; 7(1):16. PubMed ID: 34391480
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone decreases 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue.
Mai K; Andres J; Bobbert T; Maser-Gluth C; Möhlig M; Bähr V; Pfeiffer AF; Spranger J; Diederich S
Clin Endocrinol (Oxf); 2007 Sep; 67(3):419-25. PubMed ID: 17555498
[TBL] [Abstract][Full Text] [Related]
6. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Wake DJ; Stimson RH; Tan GD; Homer NZ; Andrew R; Karpe F; Walker BR
J Clin Endocrinol Metab; 2007 May; 92(5):1848-56. PubMed ID: 17327378
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.
Hamilton BS; Himmelsbach F; Nar H; Schuler-Metz A; Krosky P; Guo J; Guo R; Meng S; Zhao Y; Lala DS; Zhuang L; Claremon DA; McGeehan GM
Eur J Pharmacol; 2015 Jan; 746():50-5. PubMed ID: 25445047
[TBL] [Abstract][Full Text] [Related]
8. Influence of sub-chronic selective 11β-hydroxysteroid dehydrogenase 1 inhibition on the hypothalamic-pituitary-adrenal axis in female cynomolgus monkeys.
Hamilton BS; Schoelch C; Schuler-Metz A; Krosky P; Lala DS; Claremon DA; McGeehan GM
Eur J Pharmacol; 2016 Oct; 789():68-74. PubMed ID: 27393460
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Bianzano S; Nordaby M; Plum-Mörschel L; Peil B; Heise T
Diabetes Obes Metab; 2023 Mar; 25(3):832-843. PubMed ID: 36478142
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
[TBL] [Abstract][Full Text] [Related]
11. Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor.
Courtney R; Stewart PM; Toh M; Ndongo MN; Calle RA; Hirshberg B
J Clin Endocrinol Metab; 2008 Feb; 93(2):550-6. PubMed ID: 17986636
[TBL] [Abstract][Full Text] [Related]
12. Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.
Zhuang L; Tice CM; Xu Z; Zhao W; Cacatian S; Ye YJ; Singh SB; Lindblom P; McKeever BM; Krosky PM; Zhao Y; Lala D; Kruk BA; Meng S; Howard L; Johnson JA; Bukhtiyarov Y; Panemangalore R; Guo J; Guo R; Himmelsbach F; Hamilton B; Schuler-Metz A; Schauerte H; Gregg R; McGeehan GM; Leftheris K; Claremon DA
Bioorg Med Chem; 2017 Jul; 25(14):3649-3657. PubMed ID: 28528082
[TBL] [Abstract][Full Text] [Related]
13. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
Ge R; Huang Y; Liang G; Li X
Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
[TBL] [Abstract][Full Text] [Related]
14. In vivo activity of 11beta-hydroxysteroid dehydrogenase type 1 and free fatty acid-induced insulin resistance.
Mai K; Kullmann V; Bobbert T; Maser-Gluth C; Möhlig M; Bähr V; Pfeiffer AF; Spranger J; Diederich S
Clin Endocrinol (Oxf); 2005 Oct; 63(4):442-9. PubMed ID: 16181237
[TBL] [Abstract][Full Text] [Related]
15. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
[TBL] [Abstract][Full Text] [Related]
16. Continuous inhibition of 11β-hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice.
Morentin Gutierrez P; Gyte A; deSchoolmeester J; Ceuppens P; Swales J; Stacey C; Eriksson JW; Sjöstrand M; Nilsson C; Leighton B
Br J Pharmacol; 2015 Oct; 172(20):4806-16. PubMed ID: 26218540
[TBL] [Abstract][Full Text] [Related]
17. Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition.
Stimson RH; Andrew R; McAvoy NC; Tripathi D; Hayes PC; Walker BR
Diabetes; 2011 Mar; 60(3):720-5. PubMed ID: 21266326
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects.
Wright DH; Stone JA; Crumley TM; Wenning L; Zheng W; Yan K; Yang AY; Sun L; Cilissen C; Ramael S; Hermanowski-Vosatka A; Langdon RB; Gottesdiener KM; Wagner JA; Lai E
Br J Clin Pharmacol; 2013 Dec; 76(6):917-31. PubMed ID: 23594227
[TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes.
Heise T; Morrow L; Hompesch M; Häring HU; Kapitza C; Abt M; Ramsauer M; Magnone MC; Fuerst-Recktenwald S
Diabetes Obes Metab; 2014 Nov; 16(11):1070-7. PubMed ID: 24828020
[TBL] [Abstract][Full Text] [Related]
20. Identification of a human blood biomarker of pharmacological 11β-hydroxysteroid dehydrogenase 1 inhibition.
Gómez C; Alimajstorovic Z; Othonos N; Winter DV; White S; Lavery GG; Tomlinson JW; Sinclair AJ; Odermatt A
Br J Pharmacol; 2024 Mar; 181(5):698-711. PubMed ID: 37740611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
